New PET tracers aim to light up Hard-to-See cancers
NCT ID NCT07630961
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to compare their imaging performance and safety, not to treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-DFC413 and 68Ga-NNS309 (radioactive imaging agents)
- What this could lead to
- If successful, this could lead to better PET scans that help doctors see tumors more clearly, potentially improving cancer detection and treatment planning.
- What could go wrong
- This is a very early (Phase 1) study with only 66 people, so it is not designed to prove the imaging agents work. The agents may not show tumors clearly or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGChuo Ku, Tokyo, 1040045, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can a radioactive antibody light up hidden tumors?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Your gut bacteria might reveal hidden cancer risk